Bristol-Myers Squibb Company ((BMY)), Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Bristol-Myers Squibb and Pfizer are conducting a Phase 1b study titled A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA. The study aims to evaluate the safety and tolerability of combining elranatamab and iberdomide in patients with relapsed or refractory multiple myeloma, a challenging form of cancer that returns after treatment or resists current therapies.
Intervention/Treatment: The study tests two drugs: elranatamab, a BCMA-CD3 bispecific antibody, and iberdomide, a cereblon-modulating agent. These drugs are intended to work together to treat multiple myeloma by targeting specific pathways in cancer cells.
Study Design: This interventional study is randomized with a sequential intervention model and no masking. It is designed to determine the optimal dosing and assess the treatment’s effectiveness and safety in a structured manner.
Study Timeline: The study began on February 20, 2024, with primary completion and estimated overall completion dates yet to be specified. The latest update was submitted on July 28, 2025, indicating ongoing progress in the study.
Market Implications: This study’s progress could significantly impact the stock performance of Bristol-Myers Squibb and Pfizer, as successful results may enhance their positions in the oncology market. Investors should watch for updates, as positive outcomes could bolster investor confidence and influence market dynamics, especially in the competitive landscape of cancer treatment.
The study is currently ongoing, with further details available on the ClinicalTrials portal.